MSKai Spine Imaging Software: MSKai, an advanced image identification and post-processing software platform for spine imaging, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), authorizing its use by physicians and radiologists for lumbar spine MRI analysis.
The FDA determined that MSKai is substantially equivalent to legally marketed devices, allowing it to be marketed under the general controls of the Federal Food, Drug, and Cosmetic Act.
“The FDA’s decision confirms that MSKai meets rigorous safety and performance standards as a spine imaging tool,” said Chip Wade, Ph. D., chief operating officer at MSKai. “We’re proud to deliver a product that gives healthcare professionals enhanced capabilities in lumbar spine analysis while reinforcing the central role of expert clinical judgement.”
MSKai is a powerful tool that assists qualified medical professionals in the evaluation of previously acquired T2-weighted lumbar spine MRIs. The software enables users to perform anatomy segmentation, labeling, measurement and export of quantitative and qualitative results into customizable reports. By delivering objective, repeatable spine measurements, MSKai supports greater efficiency and consistency in clinical imaging workflows.
MSKai is not a diagnostic device and does not provide or recommend any medical diagnosis or treatment. Instead, it serves as a decision-support tool that offers clear, repeatable insights for users trained in medical imaging. Users are responsible for confirming preferences, verifying automated measurements, and finalizing reports in accordance with clinical best practices.
